He was previously at Bingham McCutchen.
In the life sciences area, Gutman concentrates his practice on developing and executing market exclusivity and freedom-to-operate strategies, including patent office and FDA regulatory strategies, for biologics, pharmaceutical, biotechnology and medical device clients. He has experience litigating biologic drug patent and Hatch-Waxman cases.
He also has experience in inter-partes patent office actions and providing strategic patent counselling.
